Roland E. Schmieder

TL;DR: The potential importance of neutral endopeptidase inhibition became obvious with the development of a new class of drugs, the so-called vasopePTidase inhibitors, which were initially developed for the treatment of hypertension and congestive heart failure, although they may also be helpful in other diseases for which angiotensin-converting enzyme (ACE) inhibitors are now used.

TL;DR: In this paper, no important difference was found in the composite renal outcome with telmisartan (58 patients [1.96%]) versus placebo (46 patients [ 1.55%]) (hazard ratio, 1.29 [95% CI, 0.87 to 1.89]; P 0.031).

TL;DR: In this article, the authors investigated the association of achieved SBP, DBP with renal outcomes and urinary albumin excretion (UAE) in people with vascular disease and found that the increased renal risk at low SBP was not related to a meaningful reduction of mandated study drugs or open label renin-angiotensin-aldosterone system inhibition.

TL;DR: In this article , a comprehensive clinical update for diabetic kidney disease (DKD) in people with type 2 diabetes, with a special focus on new treatment modalities, is provided, where the traditional strategies for prevention and treatment of DKD have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease.

TL;DR: No significant differences in cardiac output, total peripheral resistance, renal blood flow, and renal vascular resistance were found between the two racial populations, and indices of myocardial structure were comparable between black and white hypertensive patients.